Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials.

By M. Gheorghiade, M. Konstam, J. Burnett, L. Grinfeld, A. Maggioni, K. Swedberg, J. Udelson, F. Zannad, T. Cook, J. Ouyang and 2 more. Journal of the American Medical Association (JAMA), 2007

858 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Pulmonary and Respiratory Medicine, Social Psychology

View Paper: https://www.semanticscholar.org/paper/d056a73ccdebb34099e39a83fecaf4f8af484b0a

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

Citations in the corpus

ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 (2012, background): “– 216 Tolvaptan (a vasopressin V2-receptor antagonist) may be used to treat patients with resistant hyponatraemia (thirst and dehydration are recognized adverse effects).(230)”
2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. (2013, background): “oxidation, may be associated with a syndrome of progressive skeletal myopathy and cardiomyopathy (153).”
Assessing and grading congestion in acute heart failure: a scientific statement from the Acute Heart Failure Committee of the Heart Failure Association of the European Society of Cardiology and endorsed by the European Society of Intensive Care Medicine (2010, result): “placebo in patients hospitalized with worsening HF and LV ejection fraction (LVEF) ≤40%, demonstrated a significant reduction in symptoms of congestion due to loss in body fluid with tolvaptan; however, mortality and hospitalizations were unaffected when compared with placebo.(45,46) Moreover, a dru”